Combination of a matrix allosteric alkaline metalloproteinase-13 inhibitor with celecoxib or valdecoxib

摘要

"COMBINATION OF A MATRI METALOPROTEINASE-13 ALKINE ALKINE INHIBITOR WITH CELECOXIB OR VALDECOXIB". The present invention relates to a combination comprising an allosteric alkaline MMP-13 inhibitor or a pharmaceutically acceptable salt thereof with celecoxib or a pharmaceutically acceptable salt thereof or valdecoxib or a pharmaceutically acceptable salt thereof. This invention also provides a method of treating a disease which responds to inhibition of MMP-13 and cyclooxygenase-2, comprising administering to a patient suffering from such a disease the combination of the invention comprising an allosteric alkaline MMP-13 inhibitor, or a pharmaceutically acceptable salt thereof with celecoxib or a pharmaceutically acceptable salt thereof or valdecoxib or a pharmaceutically acceptable salt thereof. This invention also provides a pharmaceutical composition comprising a combination of the invention comprising an allosteric alkaline MMP-13 inhibitor, or a pharmaceutically acceptable salt thereof, with celecoxib, or a pharmaceutically acceptable salt thereof, or valdecoxib, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent or excipient. The combinations of the invention may be further combined with other pharmaceutical agents depending on the disease to be treated.